A human acellular dermal matrix coated with zinc oxide nanoparticles accelerates tendon repair in patients with hand flexor tendon injuries in zone 5 of the hand

Seyedeh-Sara Hashemi1,2,*, Mohsen Pirmoradi3, Alireza Rafati4, Mehdi Kian2,5, Ali Akbar Mohammadi1,3,*, Mohamad Ali Hoghoughi3*

1Burn and Wound Healing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Comparative Biomedical Sciences, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Fars, Iran
3Division of Plastic and Reconstructive Surgery, Department of Surgery, Shiraz University of Medical Sciences, Shiraz, Iran
4Division of Pharmacology and Pharmaceutical Chemistry, Sarvestan Branch, Islamic Azad University, Sarvestan, Iran
5Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Fars, Iran

Introduction

The function of the human wrist is intimately linked to its flexor and extensor tendons, and their malfunction impacts hand function. The flexor tendons originate from the superficial and deep flexor muscles.1,2 Verdan, in 1960, described the five distinct anatomical zones of flexor tendons, with zone 5 extending from the distal wrist crease to the flexor musculotendinous junction.3 This zone is the most exposed and so the most vulnerable zone for accidental cuts and suicidal and homicidal injuries.4 Injuries to the flexor tendons and surrounding structures are sometimes called ‘spaghetti wrists’4,5 and represent a clinical concern since they do not heal without surgery, unlike other tendons.6 The functional importance of zone structures (blood vessels, nerves, and flexor tendons) makes injuries in this area very dangerous, and

Abstract

Introduction: Flexor tendon injuries are common and require surgery. Acellular dermal matrix (ADM) is a natural graft used to repair tissues, though infections represent the primary cause of its therapeutic failure. In this study, zinc oxide nanoparticles (ZnO-NPs) were coated on the ADM in order to add antibacterial potential as well as enhance healing properties. Also, the produced ADM/ZnO-NPs graft was applied to accelerate fifth zone flexor tendon repair following the reconstructive surgery.

Methods: Morphological, mechanical, cell viability, and antibacterial tests were performed to evaluate the physical and biological properties of the fabricated ADM/ZnO-NPs graft. For clinical evaluations, 20 patients with a flexor tendon injury in zone 5 were randomly divided into control and treatment with ADM/ZnO-NPs groups (n=10 each). The control group had routine reconstructive surgery, while the other group received the ADM/ZnO-NPs graft during their surgery. Postoperative functional outcomes were evaluated 4, 6, and 8 weeks following the tendon repair surgery according to the Buck-Gramcko II criteria.

Results: The ADM/ZnO-NPs had natural derm specifications as well as dense and integrated morphology with intermediate antibacterial properties. According to the Buck-Gramcko II criteria, the postoperative functional outcome scores were significantly higher in the ADM/ZnO-NPs group in comparison with the control group at 4 (P<0.01), 6 (P<0.01), and 8 (P<0.001) weeks after the surgery.

Conclusion: The present findings revealed that the ADM/ZnO-NPs graft can accelerate the healing of the damaged tendon without common post-operative functional complications and adhesions following the tendon repair surgery. However, more comprehensive clinical trials are still needed.

© 2024 The Author(s). This work is published by BioImpacts as an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited.
impeccable management is of primary importance. All initial flexor tendon repair methods have the same basic principle: execute a surgery with minimal manipulation and sufficient repair power to allow early postoperative movement and rehabilitation, which requires the patient’s cooperation and awareness. Rupture, tendon adhesion, and joint contraction are the most prevalent consequences following flexor tendon repair. Adhesion is a normal aspect of the healing process but can also lead to tendon dysfunction. Therefore, research is in progress to develop medical strategies for preventing tendon adhesion.

Nanotechnology and tissue engineering are rising as novel fields in plastic and reconstructive surgery (PRS) that often go with regenerative medicine. Acellular dermal matrix (ADM) is a natural scaffold with high histocompatibility. This decellularized graft primarily contains collagen and serves as a great scaffold for host cell implantation and neovascularization. These properties make human ADMs widely used in wound healing, soft tissue repair, tendon repair, and sports medicine applications. ADM can be especially useful in the augmentation of tendon repair. ADMs can, in addition to mechanical tendon support, improve the healing process by revascularization, cellular growth, and re-epithelialization in hosts. The mechanical support the ADM provides reduces the risk of reinjury and adhesion of the tendon in repair procedures. The use of ADMs to augment tendon repair can also provide an additional advantage of reducing the complexity of the surgical procedure by removing the need for a second surgical site to recover autologous donor tissue and thus eliminating the risk of second-site morbidity. Furthermore, infection at the donor site can cause many problems for the patient and the surgeon. Hence, an antibacterial ADM can help prevent these problems.

Nanoparticle-based wound care solutions are relatively new compared to traditional materials. Due to their nano-size particles, nanomaterials have appropriate solubility, biocompatibility, and bioavailability in cells and tissues and stimulate repair at the cellular and molecular levels. Zinc oxide nanoparticles (ZnO-NPs) with higher bioavailability than zinc ions are very desirable for medical and pharmaceutical purposes. ZnO-NPs are recommended for their stability under punitive conditions, low toxicity, and antimicrobial, healing, anticancer, and antioxidant properties.

This study aimed to determine the outcome and devise a protocol in PRS for reducing adhesion and accelerating tendon healing in flexor zone 5 of the hands using an antibacterial ADM.

Materials and Methods

Chemicals

The ZnO-NPs were obtained from US Research Nanomaterials with ≤40 nm particle size. All chemicals and reagents were of analytical grade. Sodium chloride (NaCl), ethylenediaminetetraacetic acid (EDTA), sterile Triton X-100 surfactant, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer, sodium dodecyl sulfate (SDS), and Karnovsky’s fixative (2% paraformaldehyde, 2.5% glutaraldehyde) were purchased from Sigma Aldrich. Fetal bovine serum (FBS), Dulbecco’s modified eagle medium (DMEM), phosphate buffer saline (PBS, Tablet), amphotericin B (~80%), penicillin/ streptomycin (100X, Tissue Culture Grade), ethanol (≥99.8%), dimethyl sulfoxide (DMSO), thiazoyl blue tetrazolium bromide (98%), Dispase® I, formaldehyde solution, glutaraldehyde solution, trypan Blue, and trypsin were purchased from Sigma-Aldrich (St. Louis, MO, USA).

Preparation and evaluation of acellular dermal matrix

The ADM was produced using skin fragments taken during cosmetic abdominoplasty surgeries with the patient’s informed consent. According to the protocol used in our previous studies, after purging and elimination of subdermal fat tissues and hair, we separated the epidermis in 1 M sodium chloride (NaCl) solution shaken in the incubator at 37 °C for 18 hours. Decellularization was done with 2% SDS solution, 10 mM HEPES buffer, and EDTA solution at 25 °C for 2 hours. Then, the derm was washed thrice in sterile PBS. Before lyophilization, ZnO-NPs were coated on the ADM. To evaluate the scaffold, hematoxylin and eosin (H&E), Verhoff, and Alcian blue staining methods were utilized for all samples.

Coating ZnO-NPs on the acellular dermal matrix

Five milligrams of ZnO-NPs were dissolved in 100 mL of deionized water on a magnetic stirrer plate at 250 rpm continuously for 15 minutes at room temperature until they were equally dispersed. Then, 10 mL of ZnO-NPs solution was poured on pieces of ADM (20 mm²) and left in a sonicator bath for 10 minutes at 500 rpm to load the nanoparticles onto the matrix. Finally, the matrices were thoroughly dehumidified and dried in a freeze-dry machine. The dried components of the ADM/ZnO-NPs in the plasma machine were sanitized and disinfected before being stored at room temperature until usage.

Investigating the distribution of ZnO-NPs in ADM/ZnO-NPs scaffold

The micromorphology of ADM/ZnO-NPs was characterized by scanning electron microscopy. The scaffolds were fixed using the Karnowskfixator (2% paraformaldehyde; 2.5% glutaraldehyde), then washed with PBS and deionized water. After that, the samples were dehydrated using a graded series of ethanol solutions and dried on a Petri dish. Finally, the samples were detected using a scanning electron microscope after gold plating. Then, we analyzed the distribution of ZnO-NPs in the ADM/ZnO-NPs by scanning electron microscopy with energy-dispersive X-ray spectrometry (SEM-EDS).
**Tensile strength assay of the ADM/ZnO-NPs graft**

The tensile characteristics of the ADM/ZnO-NPs graft were determined using a uniaxial tensile test. At a speed of 10 mm/min, tape samples (50×20 mm) were cut and examined. The ASTM D882 standard was used to conduct the tensile test. The load-displacement curve was recorded, as well as the maximum tensile force when the strip broke.\(^{21}\)

**Cell viability assay**

The cell viability on the ADM/ZnO-NPs graft was determined by MTT assay. Human dermal fibroblasts (HDF1BOM; Cell Number: IBRC C10506) cultured in DMEM until the logarithmic growth stage were taken and digested by adding trypsin, then cells (1×10\(^4\) cell/96-well plate) were seeded on the membranes and incubated for 24, 48, and 72 hours. Subsequently, the MTT reagent was inserted into each well at specified times, and the plates were re-incubated for 4 hours at 37 °C. After removing the culture medium, we added DMSO into each well to dissolve the formazan. Then, the absorbance of the stained formazan yield was measured at 570 nm by an ELISA microplate reader. The MTT assay was carried out in triplicate.

**Cell proliferation assay**

The fibroblast cells' proliferation on ADM/ZnO-NPs also was assessed by staining the cell nuclei with a fluorescent dye (DAPI). The treatment was carried out on the scaffold/cells in six-well plates for 24 hours. Paraformaldehyde (4%) and Triton X100 were used to fix the cells and then washed with PBS three times. The fixed cells were incubated with DAPI (1 µg/mL) for 10 minutes for staining and washed again with PBS to discard excessive DAPI before observing under fluorescent microscopy (Olympus, Japan) at a peak excitation wavelength of 340 nm.

**In vitro antibacterial activity of ADM/ZnO-NPs**

To measure the antimicrobial efficacy, we prepared suspensions of *Staphylococcus aureus* (ATCC 25923) and *Escherichia coli* (ATCC 25922) on the surface of Mueller-Hinton agar plates. Then, circles with a diameter of 5 mm from ADM/ZnO-NPs and ADM (control) were cut and placed onto the agar plates. A tetracycline disc was used as the positive control. The diameter of the inhibition zone (DIZ) was measured using a metric ruler after a 24-hour incubation at 37 °C.

**Study design**

Twenty patients above 18 years old with acute flexor zone 5 injuries without severe bone lesions were chosen. Patients with injuries were not allowed to participate in the research. The research was carried out at Rajaei Medical Center and informed written consent was obtained from all patients. Demographic information, type of injury, and location were obtained through interviews with the patients. Information on the presence of associated lesions and the type of tendon injury was extracted through clinical examination and wound exploration during surgery (Table 1). Whole blood tests and radiographic investigations were done before surgery.

After resuscitation and pain management, a full limb examination, proximal and distal neurovascular assessment, and skeletal muscle examination were performed as painlessly as feasible. The examination was halted until the patient had been anesthetized. Under general anesthesia, all patients had surgery with a control tourniquet and loupe magnification. Except in cases where both the ulnar and radial arteries were cut and the hand required re-arterialization, the tendons were restored first, followed by the nerves and, ultimately, the arteries. For tendon repair, the core suture repairing technique by four-strand suture with Nylon 3/0 was employed. The tendon repair after the core suture was completed by circumferential epitenidinous suturing with Nylon 4/0. In the case of nerve damage, it was repaired with Prolene 8/0.

To lessen the complications caused by tendon adhesion, in the treatment group (10 patients), the ADM/ZnO-NPs in desirable size were inserted in the repair site and fixed with Monocryl 4/0. The control group (10 patients) did not receive the ADM/ZnO-NPs. Postoperative physiotherapy was started for all patients after 24 hours. Following the removal of the splint during physiotherapy, the patient’s activity was monitored for 2 weeks with active extension controlled passive flexion and passive range of motion exercises, followed by four weeks of holding objects without exerting pressure. After six weeks, holding and lifting light-weight objects were allowed with progressively increasing resistance to flexion. After 6 weeks, the splint was worn only at night for another 2 weeks.

**Postoperative clinical evaluations**

The functional outcome of flexor tendon repair was assessed by Buck-Gramcko II criteria based on the nail-to-palm crease distance, total extension defect, and modified total active motion score after eight weeks. Based on the score received, the results were evaluated using a four-stage classification system.\(^{28}\)

**Statistical analysis**

All data are expressed as mean ± standard deviation (SD). GraphPad Prism (version 9.3.1, GraphPad Software, Inc., La Jolla, CA, USA) statistical software was used for all statistical analyses. Comparisons between the groups were performed using the unpaired t-test, two-way analysis of variance (ANOVA), and Fisher’s exact test, as appropriate. \(P < 0.05\) was considered to reflect statistical significance.

**Results**

**Histological evaluation of the ADM scaffold and SEM analysis of ADM and ADM/ZnO-NPs graft**

After H&E staining of ADM, no cells were detected,
and the collagen fibers were stained in red. ADM staining Using Verhoff and Alcianblue staining methods directed the presence of elastin fibers in black color and glycosaminoglycans in blue color revealed in the ADM scaffold (Fig. 1). Cross-sectional SEM analysis revealed that after the acellularization process, no cells existed in the ADM/ZnO-NPs scaffold, with only the normal appearance of the dermal collagen structure and nanoparticles being visible in the SEM micrograph.

Fig. 2 shows the SEM image and the EDS spectrum of ADM/ZnO-NPs. Yellow, gray, and purple dots represent the distribution of C, O, and Zn within the ADM. As it is obvious, elements, especially O and Zn, are distributed homogeneously.
Mechanical evaluation of the ADM/ZnO-NPs graft
The results of mechanical evaluations can be seen in Fig. 3. Load-displacement curves of ADM and ADM/ZnO-NPs graft are illustrated in Fig. 3A. The maximum tensile force in the ADM/ZnO-NPs scaffold (172.2 ± 10.87 MPa) was significantly ($P<0.05$) higher than in the ADM scaffold (152.7 ± 10.89 MPa) (Fig. 3B).

Cell viability of human dermal fibroblasts in the ADM/ZnO-NPs scaffold
The results of the cell viability assay are represented in Fig. 4A. At 24 and 48 hours, the percentage of cell viability in the ADM (105.73 ± 12.02 and 145.28 ± 7.70, respectively) and ADM/ZnO-NPs (120.44 ± 9.75 and 166.05 ± 9.90, respectively) scaffold had no significant difference. At 72 hours, the cell viability was remarkably ($P<0.05$) higher in the ADM/ZnO-NPs scaffold (176.07 ± 5.21) in comparison with the ADM graft (155.75 ± 3.63).

Disk diffusion antibacterial assay for the ADM/ZnO-NPs graft
The disc diffusion assay demonstrated that the ADM/ZnO-NPs graft was effective against *S. aureus* and *E. coli* (Fig. 5A and B, respectively). The DIZ of ADM/ZnO-NPs samples was 3.85 ± 0.72 mm for *S. aureus* and 6.24 ± 1.08 mm for *E. coli* (Fig. 5C and D, respectively). Both control and ADM samples did not have an inhibition zone.

Patients’ demographics
The mean age was 31.70 ± 8.97 and 30.70 ± 30.70 years in the control and ADM/ZnO-NPs groups, respectively, and no significant difference was found between the groups. In each group, nine (90%) patients were males, and 1 (10%) patient was female (Table 2).
Postoperative evaluation

Functional outcomes according to the Buck-Gramcko II criteria are shown in Fig. 6. After four weeks, 20% of patients in the control group had a poor outcome, 70% of them had a fair outcome, and 10% had a good outcome. At the same time, patients in the ADM/ZnO-NPs group had 40% fair and 60% good outcomes. After six weeks, functional outcomes in the control group were 40% poor, 50% fair, and 10% excellent; in the ADM/ZnO-NPs group, they were 70% good and 30% excellent. After 8 weeks, 60% of patients in the control group had a good outcome, and the other 40% had an excellent outcome. At all-time intervals, patients in the ADM/ZnO-NPs group had significantly higher outcome points than those in the control group.

Fig. 7 shows the postoperative clinical evaluation of the flexion of fingers in two cases after 28 days (A-D and E-H, respectively). As it is obvious, both patients could successfully flex their fingers.

Discussion

Lacerations to the volar wrist surface have the potential to be severely debilitating, mainly due to the superficial location and high density of tendons, nerves, and arteries in that area. Adhesion formation post-tendon repair represents a major challenge. Different options for preventing adhesions after flexor tendon repair have been introduced: modifying the suture technique, optimizing postoperative resting, regulating tissue remodeling and inflammation, and placing mechanical barriers between the tendons and tissues for maintaining a gliding surface. ADM/ZnO-NPs act as a barrier between the tendons and proliferating tissues, promoting healing and preventing adhesion.

This graft is ideal for tissue healing because it not only provides a proper environment for fibroblast cells to multiply and migrate but also does not trigger the patient’s immune system due to its cell-free nature. With the existence of collagen types I and III,
elastin fibers, glycosaminoglycans (GAGs), glycoproteins (GPs), proteoglycans (PGs), fibronectin, fibrin, heparin, and integrin, this product is ideal for connecting, proliferating, and migrating skin cells. Hence, we investigated the physical and chemical characteristics of ADM/ZnO-NPs, including tensile strength, morphology, viability, and antibacterial characteristics. Our findings revealed that the ZnO-NPs did not affect the biomechanical or biological characteristics of ADM. According to histological examinations, elastin fibers and the secretory matrix of glycosaminoglycans were found in the scaffold, indicating that the dermis in ADM/ZnO-NPs had a complete and adequate structure. Scanning electron microscopy validated the dense and integrated structure of ADM/ZnO-NPs. ZnO-NPs on ADM can produce considerable antibacterial capabilities against both Gram-positive and Gram-negative bacteria. As a result of its antibacterial activity, no infection can be noticed in the surgical area of the flexor tendon using this scaffold.

In line with our findings, previous studies have reported that loading metal-NPs on the ADM reinforced their physiochemical properties and added antibacterial activity to them. Chen et al have indicated that porcine ADM graft containing silver-NPs not only had better structural and thermal stability but also exhibited remarkable antibacterial properties and enhanced wound healing. Similarly Tao et al have revealed that ADMs immersed in different concentrations of the silver-NPs possess antibacterial activity as well as an accelerated healing process while decreasing intraperitoneal adhesion and surgical site infection in a rat model of abdominal wall defect.

In this study, all 20 patients successfully underwent zone 5 augmented flexor tendon repair surgery. No patient showed any signs of infection or had an adverse reaction to the ADM/ZnO-NPs. Therefore, the ADM/ZnO-NPs scaffold has various factors that facilitate recovery and return of hand function after tendon repair. Despite the shortage of similar clinical studies on zone 5 flexor tendon injuries, our study indicates the benefits of using the specified allograft in such cases. The complete absence of both infections and postoperative complications is also notable, though these findings should be interpreted with caution considering the small sample size. To the best knowledge of the authors, this study is the first clinical trial that developed a modified ADM with antibacterial properties and applied it for repairing tendon damage.

Cole et al used an ADM to restore the Achilles tendon, showing that the surgery was fully successful without incidences of rupture or difficulties that needed

---

**Fig 6.** (A-C) The recovery classification and (D-E) recorded points from the function of flexor tendons in zone 5 using Buck-Gramcko II criteria at 4, 6, and 8 weeks after surgery, respectively. **P<0.01 and ***P<0.001.

**Fig 7.** Postoperative photographs show successful flexion of fingers in two cases (A-D and E-H, respectively).
extra therapy. Branch and colleagues studied tendon transplanting with an ADM to repair the Achilles tendon and other leg and ankle tendons and found that lower volumes of ADM produce more strength in the tendon. In another study, animals with rotator cuff tendon abnormalities were given a topical treatment of fibroblast growth factor along with ADM; the results proved that ADM was effective.

Based on the Buck-Gramcko II criteria, the functional outcomes of the flexor tendon in zone 5 following surgery were better in the ADM/ZnO-NPs group compared with the control group. This could be because the use of ADM/ZnO-NPs in flexor tendon zone 5 resulted in less infection and adhesion in the injured area after healing.

Although the allograft might not have augmented healing, the absence of infection supports the safe use of allografts in flexor tendon repair procedures. However, the lack of similar studies made comparisons difficult, which also denotes the importance of small pilot studies. Future investigators could use the present results in developing more rigorous randomized controlled trials or prospective cohort studies.

The limitation of the present clinical trial was the small patient population and unblinded outcomes assessors.

Conclusion
The present study confirmed that ADM/ZnO-NPs, as an anti-adhesion barrier, can improve functional consequences after surgery in patients with an injured zone 5 flexor tendon. Our findings indicate that ADM/ZnO-NPs can help repair the damaged area without complications and adhesion in tendon repair surgery, though more comprehensive clinical trials are needed.

Acknowledgments
The authors wish to thank the respected colleagues and staff of Shahid Rajee Hospital at Shiraz University of Medical Sciences for their invaluable assistance.

Funding sources
The authors did not receive support from any organization for the submitted work.

Ethical Statement
This study was approved by the Ethics Committee of Shiraz University of Medical Sciences, Shiraz, Iran (Ethical code: IR.SUMS.MED.REC.1400.377; Approval code: 15203). All experiments were directed according to the ethical standards of the 1964 Helsinki Declaration.

Competing Interests
The authors declare no conflicts of interest.

Authors’ contribution
Conceptualization: Seyedeh-Sara Hashemi, Ali Akbar Mohammadi and Mohammad Ali Hoghoughi
Data curation: Seyedeh-Sara Hashemi and Mohsen Pirmoradi
Formal analysis: Seyedeh-Sara Hashemi, Alireza Rafati and Mehdi Kian
Funding acquisition: Seyedeh-Sara Hashemi, Mohsen Pirmoradi and Ali Akbar Mohammadi
Investigation: Seyedeh-Sara Hashemi, Mohsen Pirmoradi and Alireza Rafati
Methodology: Seyedeh-Sara Hashemi, Ali Akbar Mohammadi and Mohammad Ali Hoghoughi
Project administration: Seyedeh-Sara Hashemi, Ali Akbar Mohammadi and Mohammad Ali Hoghoughi
Software: Seyedeh-Sara Hashemi, Mohsen Pirmoradi and Mehdi Kian
Supervision: Ali Akbar Mohammadi and Mohammad Ali Hoghoughi
Validation: Seyedeh-Sara Hashemi, Mohsen Pirmoradi, Ali Akbar Mohammadi and Mohammad Ali Hoghoughi
Visualization: Seyedeh-Sara Hashemi, Mohsen Pirmoradi and Ali Akbar Mohammadi
Writing–original draft: Mohsen Pirmoradi, Alireza Rafati and Mehdi Kian
Writing–review & editing: Seyedeh-Sara Hashemi, Alireza Rafati and Mehdi Kian

References


